Abeona Therapeutics (NASDAQ:ABEO) Director Sells $65,120.00 in Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Leila Alland sold 11,000 shares of Abeona Therapeutics stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $5.92, for a total transaction of $65,120.00. Following the completion of the transaction, the director directly owned 162,614 shares of the company’s stock, valued at $962,674.88. The trade was a 6.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Abeona Therapeutics Price Performance

ABEO traded up $0.35 during trading on Thursday, hitting $6.40. The company’s stock had a trading volume of 1,395,852 shares, compared to its average volume of 1,202,640. The business’s fifty day simple moving average is $5.61 and its 200 day simple moving average is $5.25. Abeona Therapeutics Inc. has a twelve month low of $4.00 and a twelve month high of $7.54. The firm has a market capitalization of $364.77 million, a price-to-earnings ratio of 6.60 and a beta of 1.33. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $4.57 million. On average, equities research analysts forecast that Abeona Therapeutics Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on ABEO. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Stifel Nicolaus set a $17.00 target price on shares of Abeona Therapeutics in a report on Tuesday, March 17th. Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Weiss Ratings upgraded Abeona Therapeutics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday. Finally, Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research report on Monday, March 9th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $19.00.

Institutional Investors Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ABEO. Goldman Sachs Group Inc. lifted its position in shares of Abeona Therapeutics by 49.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after acquiring an additional 66,422 shares during the period. Geode Capital Management LLC increased its stake in Abeona Therapeutics by 129.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after purchasing an additional 623,243 shares in the last quarter. Creative Planning increased its stake in Abeona Therapeutics by 43.0% in the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 4,305 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Abeona Therapeutics by 255.6% during the second quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock worth $4,721,000 after purchasing an additional 597,373 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Abeona Therapeutics during the second quarter worth $27,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.